A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma
Undifferentiated high-grade pleomorphic sarcoma (UHPS) is a rare soft tissue sarcoma (STS) originated from mesenchyme. UHPS is mostly advanced, aggressive and has poor prognosis. Patients with UHPS tend to have a lower 5-year survival rate than patients with other types of STS. NTRK fusions are comm...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2022-10, Vol.148 (10), p.2933-2937 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2937 |
|---|---|
| container_issue | 10 |
| container_start_page | 2933 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 148 |
| creator | Bai, Chujie Zhang, Lu Wang, Yaohui You, Xia Ju, Yongzhi Sun, Tingting Fan, Zhengfu |
| description | Undifferentiated high-grade pleomorphic sarcoma (UHPS) is a rare soft tissue sarcoma (STS) originated from mesenchyme. UHPS is mostly advanced, aggressive and has poor prognosis. Patients with UHPS tend to have a lower 5-year survival rate than patients with other types of STS.
NTRK
fusions are commonly found in rare histological tumor types. Among sarcomas, 90% of infantile fibrosarcomas have
NTRK
fusions. Many other types of sarcomas have also been studied for
NTRK
fusions. Targeted therapy with NTRK inhibitors, such as Larotrectinib and Entrectinib, leads to response in most patients with
NTRK1/2/3
gene fusion-positive tumors. Herein, we present a 68-years old man with UHPS by pathological diagnosis. Next-generation sequencing (NGS) revealed a novel
TMTC2-NTRK3
fusion, which was also detected by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). This report broadens the spectrum of
NTRK
fusions in UHPS and highlights a new target for treatment. |
| doi_str_mv | 10.1007/s00432-022-04249-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2713850674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2713850674</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-32c812b3ea863a249b842dad362e85d15d9a3c71c08edc1e9c50d6b4b8980ed33</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoWKt_wFPAczQf-5E9lqJWbBVkPYdsMttuaTdrsiv135u6gjcPwzDD-74zPAhdM3rLKM3vAqWJ4ITyWAlPCnI4QRN2XDEh0lM0oSxnJOUsO0cXIWxpnNOcT9Bqhlv3CTtcrso5Jy_l27PA9RAa1-KmxUNrm7oGD23f6B4s3jTrDVl7bQF3O3B757tNY3DQ3ri9vkRntd4FuPrtU_T-cF_OF2T5-vg0ny2JEazoieBGMl4J0DITOr5byYRbbUXGQaaWpbbQwuTMUAnWMChMSm1WJZUsJAUrxBTdjLmddx8DhF5t3eDbeFLxnAmZ0ixPooqPKuNdCB5q1flmr_2XYlQdsakRm4rY1A82dYgmMZpCFLdr8H_R_7i-AXiLb4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2713850674</pqid></control><display><type>article</type><title>A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma</title><source>SpringerLink Journals - AutoHoldings</source><creator>Bai, Chujie ; Zhang, Lu ; Wang, Yaohui ; You, Xia ; Ju, Yongzhi ; Sun, Tingting ; Fan, Zhengfu</creator><creatorcontrib>Bai, Chujie ; Zhang, Lu ; Wang, Yaohui ; You, Xia ; Ju, Yongzhi ; Sun, Tingting ; Fan, Zhengfu</creatorcontrib><description>Undifferentiated high-grade pleomorphic sarcoma (UHPS) is a rare soft tissue sarcoma (STS) originated from mesenchyme. UHPS is mostly advanced, aggressive and has poor prognosis. Patients with UHPS tend to have a lower 5-year survival rate than patients with other types of STS.
NTRK
fusions are commonly found in rare histological tumor types. Among sarcomas, 90% of infantile fibrosarcomas have
NTRK
fusions. Many other types of sarcomas have also been studied for
NTRK
fusions. Targeted therapy with NTRK inhibitors, such as Larotrectinib and Entrectinib, leads to response in most patients with
NTRK1/2/3
gene fusion-positive tumors. Herein, we present a 68-years old man with UHPS by pathological diagnosis. Next-generation sequencing (NGS) revealed a novel
TMTC2-NTRK3
fusion, which was also detected by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). This report broadens the spectrum of
NTRK
fusions in UHPS and highlights a new target for treatment.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-022-04249-x</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer Research ; Correspondence ; Fluorescence in situ hybridization ; Gene fusion ; Hematology ; Immunohistochemistry ; Internal Medicine ; Medicine ; Medicine & Public Health ; Mesenchyme ; Next-generation sequencing ; Oncology ; Patients ; Soft tissue sarcoma ; Tumors</subject><ispartof>Journal of cancer research and clinical oncology, 2022-10, Vol.148 (10), p.2933-2937</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c319t-32c812b3ea863a249b842dad362e85d15d9a3c71c08edc1e9c50d6b4b8980ed33</citedby><cites>FETCH-LOGICAL-c319t-32c812b3ea863a249b842dad362e85d15d9a3c71c08edc1e9c50d6b4b8980ed33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-022-04249-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-022-04249-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Bai, Chujie</creatorcontrib><creatorcontrib>Zhang, Lu</creatorcontrib><creatorcontrib>Wang, Yaohui</creatorcontrib><creatorcontrib>You, Xia</creatorcontrib><creatorcontrib>Ju, Yongzhi</creatorcontrib><creatorcontrib>Sun, Tingting</creatorcontrib><creatorcontrib>Fan, Zhengfu</creatorcontrib><title>A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><description>Undifferentiated high-grade pleomorphic sarcoma (UHPS) is a rare soft tissue sarcoma (STS) originated from mesenchyme. UHPS is mostly advanced, aggressive and has poor prognosis. Patients with UHPS tend to have a lower 5-year survival rate than patients with other types of STS.
NTRK
fusions are commonly found in rare histological tumor types. Among sarcomas, 90% of infantile fibrosarcomas have
NTRK
fusions. Many other types of sarcomas have also been studied for
NTRK
fusions. Targeted therapy with NTRK inhibitors, such as Larotrectinib and Entrectinib, leads to response in most patients with
NTRK1/2/3
gene fusion-positive tumors. Herein, we present a 68-years old man with UHPS by pathological diagnosis. Next-generation sequencing (NGS) revealed a novel
TMTC2-NTRK3
fusion, which was also detected by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). This report broadens the spectrum of
NTRK
fusions in UHPS and highlights a new target for treatment.</description><subject>Cancer Research</subject><subject>Correspondence</subject><subject>Fluorescence in situ hybridization</subject><subject>Gene fusion</subject><subject>Hematology</subject><subject>Immunohistochemistry</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mesenchyme</subject><subject>Next-generation sequencing</subject><subject>Oncology</subject><subject>Patients</subject><subject>Soft tissue sarcoma</subject><subject>Tumors</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kE1LAzEQhoMoWKt_wFPAczQf-5E9lqJWbBVkPYdsMttuaTdrsiv135u6gjcPwzDD-74zPAhdM3rLKM3vAqWJ4ITyWAlPCnI4QRN2XDEh0lM0oSxnJOUsO0cXIWxpnNOcT9Bqhlv3CTtcrso5Jy_l27PA9RAa1-KmxUNrm7oGD23f6B4s3jTrDVl7bQF3O3B757tNY3DQ3ri9vkRntd4FuPrtU_T-cF_OF2T5-vg0ny2JEazoieBGMl4J0DITOr5byYRbbUXGQaaWpbbQwuTMUAnWMChMSm1WJZUsJAUrxBTdjLmddx8DhF5t3eDbeFLxnAmZ0ixPooqPKuNdCB5q1flmr_2XYlQdsakRm4rY1A82dYgmMZpCFLdr8H_R_7i-AXiLb4w</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Bai, Chujie</creator><creator>Zhang, Lu</creator><creator>Wang, Yaohui</creator><creator>You, Xia</creator><creator>Ju, Yongzhi</creator><creator>Sun, Tingting</creator><creator>Fan, Zhengfu</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20221001</creationdate><title>A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma</title><author>Bai, Chujie ; Zhang, Lu ; Wang, Yaohui ; You, Xia ; Ju, Yongzhi ; Sun, Tingting ; Fan, Zhengfu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-32c812b3ea863a249b842dad362e85d15d9a3c71c08edc1e9c50d6b4b8980ed33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer Research</topic><topic>Correspondence</topic><topic>Fluorescence in situ hybridization</topic><topic>Gene fusion</topic><topic>Hematology</topic><topic>Immunohistochemistry</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mesenchyme</topic><topic>Next-generation sequencing</topic><topic>Oncology</topic><topic>Patients</topic><topic>Soft tissue sarcoma</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bai, Chujie</creatorcontrib><creatorcontrib>Zhang, Lu</creatorcontrib><creatorcontrib>Wang, Yaohui</creatorcontrib><creatorcontrib>You, Xia</creatorcontrib><creatorcontrib>Ju, Yongzhi</creatorcontrib><creatorcontrib>Sun, Tingting</creatorcontrib><creatorcontrib>Fan, Zhengfu</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Chujie</au><au>Zhang, Lu</au><au>Wang, Yaohui</au><au>You, Xia</au><au>Ju, Yongzhi</au><au>Sun, Tingting</au><au>Fan, Zhengfu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><date>2022-10-01</date><risdate>2022</risdate><volume>148</volume><issue>10</issue><spage>2933</spage><epage>2937</epage><pages>2933-2937</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Undifferentiated high-grade pleomorphic sarcoma (UHPS) is a rare soft tissue sarcoma (STS) originated from mesenchyme. UHPS is mostly advanced, aggressive and has poor prognosis. Patients with UHPS tend to have a lower 5-year survival rate than patients with other types of STS.
NTRK
fusions are commonly found in rare histological tumor types. Among sarcomas, 90% of infantile fibrosarcomas have
NTRK
fusions. Many other types of sarcomas have also been studied for
NTRK
fusions. Targeted therapy with NTRK inhibitors, such as Larotrectinib and Entrectinib, leads to response in most patients with
NTRK1/2/3
gene fusion-positive tumors. Herein, we present a 68-years old man with UHPS by pathological diagnosis. Next-generation sequencing (NGS) revealed a novel
TMTC2-NTRK3
fusion, which was also detected by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). This report broadens the spectrum of
NTRK
fusions in UHPS and highlights a new target for treatment.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00432-022-04249-x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2022-10, Vol.148 (10), p.2933-2937 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_journals_2713850674 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Cancer Research Correspondence Fluorescence in situ hybridization Gene fusion Hematology Immunohistochemistry Internal Medicine Medicine Medicine & Public Health Mesenchyme Next-generation sequencing Oncology Patients Soft tissue sarcoma Tumors |
| title | A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T19%3A35%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20novel%20TMTC2-NTRK3%20fusion%20in%20undifferentiated%20high-grade%20pleomorphic%20sarcoma&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Bai,%20Chujie&rft.date=2022-10-01&rft.volume=148&rft.issue=10&rft.spage=2933&rft.epage=2937&rft.pages=2933-2937&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-022-04249-x&rft_dat=%3Cproquest_cross%3E2713850674%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2713850674&rft_id=info:pmid/&rfr_iscdi=true |